Status:

COMPLETED

Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel

Lead Sponsor:

Pfizer

Conditions:

Spondyloarthrosis

Eligibility:

All Genders

18+ years

Brief Summary

This study is to evaluate local data in Iraqi patients with Spondyloarthropathies on Enbrel treatment with regards to efficacy and adherence using data from the Baghdad Teaching Hospital (Rheumatology...

Eligibility Criteria

Inclusion

  • Diagnosed SpA patients
  • 18 years of age and older.
  • Did not receive previous other biological treatments.
  • Patients have at least 1 year on Enbrel.

Exclusion

  • Had previously used another biological treatments.
  • Use of etanercept for less than 1 year duration.

Key Trial Info

Start Date :

September 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 1 2020

Estimated Enrollment :

763 Patients enrolled

Trial Details

Trial ID

NCT04507776

Start Date

September 1 2020

End Date

October 1 2020

Last Update

October 4 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Pfizer

Baghdad, Iraq